Genetic and Environmental Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Status: Recruiting
Location: See all (10) locations...
Intervention Type: Procedure, Device
Study Type: Observational
SUMMARY

The overall objectives of this BETRNet Research Center (RC) are: 1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA) 2. to increase the biological understanding of key observations made by our clinical researchers; 3. to translate knowledge derived from genetic, epigenetic, and transcriptome research to solving clinical dilemmas in detection, prognosis, prevention, and therapy of BE in order to prevent EAC and improve the outcomes of EAC; 4. to foster a transdisciplinary and translation research culture and to effectively expand and enhance scientific research focused on BE and EAC; 5. to evaluate research and transdisciplinary programs and to continuously improve research, productivity and enhance translational implementation. These objectives build and synergize on existing multi-institutional collaborative networks and the considerable clinical, basic science, and translational expertise available at our institutions, focusing on improving the outcomes of patients with BE and EAC. The overarching organization framework for this RC proposal is 1) to focus laboratory research on understanding the genetic susceptibility, genomic and epigenetic changes that influence the development of BE and EAC; and 2) to then translate laboratorydiscoveries into clinical applications for effective detection, molecular risk stratification, and prevention of progression from BE to EAC.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

⁃ Eligible cases will be defined as those patients and their family members who meet the following criteria:

• Barrett's esophagus confirmed by review of pathology and endoscopy report or adenocarcinoma of the esophagus or family members of person with Barrett's esophagus or adenocarcinoma of the esophagus.

• Male or female age 18 or older at time of enrollment or male or female less than 18 years of age at time of enrollment with parental consent.

• Ability to give informed consent, if patient is age 18 or older.

Locations
United States
Maryland
Johns Hopkins Hospital
RECRUITING
Baltimore
Minnesota
Mayo Clinic
RECRUITING
Rochester
Missouri
Washington University School of Medicine
RECRUITING
St Louis
North Carolina
University of North Carolina at Chapel Hill
RECRUITING
Chapel Hill
New York
Columbia University Medical Center
RECRUITING
New York
Ohio
Cleveland Clinic
RECRUITING
Cleveland
University Hospitals of Cleveland
RECRUITING
Cleveland
Pennsylvania
University of Pennsylvania
RECRUITING
Philadelphia
Washington
Fred Hutchinson Cancer Research Center, UWMC
RECRUITING
Seattle
VA Puget Sound Health Care System
RECRUITING
Seattle
Contact Information
Primary
Amitabh Chak, MD
axc22@po.cwru.edu
216-844-5385
Backup
Wendy Brock, RN
wendy.brock@UHhospitals.org
216-844-3853
Time Frame
Start Date: 2005-10-01
Estimated Completion Date: 2028-07-31
Participants
Target number of participants: 2000
Treatments
Cases
Patients with Barrett's esophagus undergoing surveillance or patients with esophageal adenocarcinoma and esophagogastric junctional adenocarcinoma undergoing EGD
EGD Screening
Patients scheduled for clinically indicated EGD for GERD who meet ACG criteria for BE screening
Colon Screening
Patients scheduled for screening colonoscopy who have not had EGD and meet clinically indicated criteria for BE screening
Controls
Patients scheduled for EGD who do not meet criteria for screening
Sponsors
Collaborators: Mayo Clinic, Washington University School of Medicine, University of Pennsylvania, Mercy Medical Center, VA Puget Sound Health Care System, Columbia University, University of Washington, Fred Hutchinson Cancer Center, The Cleveland Clinic, Johns Hopkins University, University Hospitals Cleveland Medical Center, University of North Carolina, Chapel Hill
Leads: Case Western Reserve University

This content was sourced from clinicaltrials.gov